Speakers Announced for Virtual Experimental Biology 2021 Meeting

Renowned scientists—including Nobel laureates, research pioneers and celebrated educators—will speak at the virtual Experimental Biology (EB) 2021 meeting, to be held April 27–30. Bringing together thousands of life scientists in one interdisciplinary community, EB showcases the latest advances in anatomy, biochemistry, molecular biology, investigative pathology, pharmacology and physiology.

Press Registration Now Open for Virtual Experimental Biology 2021 Meeting

Complimentary press passes are now available for the virtual Experimental Biology (EB) 2021 meeting, to be held April 27–30. EB is the annual meeting of five scientific societies bringing together thousands of scientists and 25 guest societies in one interdisciplinary community.

10 ways Argonne science is combatting COVID-19

Argonne scientists and research facilities have made a difference in the fight against COVID-19 in the year since the first gene sequence for the virus was published.

Finding The Achilles’ Heel of A Killer Parasite

DALLAS – Sept. 24, 2020 – Two studies led by UT Southwestern researchers shed light on the biology and potential vulnerabilities of schistosomes – parasitic flatworms that cause the little-known tropical disease schistosomiasis. The findings, published online today in Science, could change the course of this disease that kills up to 250,000 people a year.

Seeing Corneal Degeneration in A New Light

DALLAS – June 17, 2020 – The molecular changes that lead to Fuchs’ endothelial corneal dystrophy (FECD) occur decades before the disease causes blurry vision and other noticeable symptoms in patients, new research by UT Southwestern scientists shows. This insight into this earliest stage of FECD may eventually lead to new ways of screening for and treating the common condition, which affects an estimated 4 percent of U.S. adults over the age of 40.

Argonne’s researchers and facilities playing a key role in the fight against COVID-19

Argonne scientists are working around the clock to analyze the virus to find new treatments and cures, predict how it will propagate through the population, and make sure that our supply chains remain intact.

Choosing Common Pain Relievers: It’s Complicated

About 29 million Americans use over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) to treat pain. Every year in the U.S., NSAID use is attributed to approximately 100,000 hospitalizations and 17,000 deaths. All of these drugs have benefits and risks, but deciding which one to use is complicated for health care providers and their patients. To assist in clinical decision-making, researchers address cardiovascular risks and beyond, which include gastrointestinal and kidney side effects of pain relievers.